首页> 外国专利> PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED

PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED

机译:用于预防和治疗眼部疾病的药物组合物,含有作为活性成分的融合蛋白,其中融合了组织穿透肽和抗血管内皮生长因子制剂

摘要

The present invention relates to a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial growth factor (anti-VEGF) preparation are fused. More particularly, the present invention relates to: a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused; a method for prepraring an anti-VEGF preparation, which overcomes resistance and has an improved efficacy, the method comprising the steps of transforming a host cell with a recombinant vector comprising a nucleic acid sequence encoding a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused, culturing the cell, and recovering a fusion protein from the cell; a method for treating eye diseases, comprising administering an effective dose of the fusion protein according to the present invention to a subject in need thereof; and use of the fusion protein according to the present invention for preparing an agent for treating eye diseases. Compared to conventional anti-VEGF preparations, the composition according to the present invention is considered to have an improved efficacy and be able to be used for treating patients having drug resistance, by inhibiting various growth factors related to new blood vessels, besides VEGF, and by decreasing pericyte coverage. In addition, since drug delivery ability into the choroid tissue is improved when performing an intraocular injection, the composition can be developed as eye drops by reducing an administered dosage or extending an administration cycle, and by improving ocular penetrability.
机译:本发明涉及一种用于预防和治疗眼部疾病的药物组合物,其包含作为活性成分的融合蛋白,其中融合组织穿透肽和抗血管内皮生长因子(抗VEGF)制剂。更具体地说,本发明涉及:一种用于预防和治疗眼部疾病的药物组合物,其包含作为活性成分的融合蛋白,其中融合组织穿透肽和抗VEGF制剂;一种用于预制备抗VEGF制剂的方法,其克服了耐药性并具有改进的功效,所述方法包括以下步骤:用重组载体转化宿主细胞,所述重组载体包含编码融合蛋白的核酸序列,其中组织穿透肽和抗VEGF制剂在其中融合,培养所述细胞,并从所述细胞中回收融合蛋白;一种治疗眼部疾病的方法,包括向需要的受试者投与有效剂量的根据本发明的融合蛋白;以及根据本发明的融合蛋白在制备治疗眼病的药剂中的用途。与传统抗VEGF制剂相比,根据本发明的组合物被认为具有改进的功效,并且能够通过抑制除VEGF外与新血管相关的各种生长因子以及通过降低周细胞覆盖率来用于治疗具有耐药性的患者。此外,由于在进行眼内注射时药物进入脉络膜组织的能力得到改善,因此该组合物可以通过减少给药剂量或延长给药周期,以及通过改善眼部穿透性而开发为滴眼剂。

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号